Provided by Tiger Trade Technology Pte. Ltd.

iBio

1.11
-0.0700-5.93%
Pre-market: 1.160.0500+4.50%07:24 EDT
Volume:340.42K
Turnover:387.51K
Market Cap:71.38M
PE:-3.50
High:1.21
Open:1.18
Low:1.10
Close:1.18
52wk High:3.82
52wk Low:0.7811
Shares:64.31M
Float Shares:52.11M
Volume Ratio:0.97
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3175
EPS(LYR):-0.3175
ROE:-65.70%
ROA:-30.80%
PB:0.83
PE(LYR):-3.50

Loading ...

Oppenheimer Reaffirms Their Buy Rating on Ibio (IBIO)

TIPRANKS
·
May 14

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR)

TIPRANKS
·
May 13

BRIEF-Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update

Reuters
·
May 13

iBio reports Q3 EPS (7c), consensus (6c)

TIPRANKS
·
May 13

iBio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

iBio Q3 EPS $(0.07) Misses $(0.06) Estimate

Benzinga Earnings
·
May 13

iBio wins Australian clearance to start Phase 1 trial of obesity drug IBIO-600

Reuters
·
May 13

iBio FY26 Q3 net loss widens to $7.73 million; operating loss widens to $8.37 million

Reuters
·
May 13

Ibio Inc - Reports No Revenue for Q3 Ended March 31, 2026

THOMSON REUTERS
·
May 13

Ibio Inc: Qtrly Loss per Share $-0.07

THOMSON REUTERS
·
May 13

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 13

iBio Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
May 08

iBio names Elizabeth Stoner to board as Schimmelpennink steps down

Reuters
·
May 08

Ibio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to Its Board of Directors

THOMSON REUTERS
·
May 08

Press Release: iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

Dow Jones
·
May 08

iBio Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
Apr 28

iBio amends 8-K to correct Series G warrants expiration date to May 20, 2026

Reuters
·
Apr 18

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
Apr 09

Ibio (IBIO) Receives a Buy from Chardan Capital

TIPRANKS
·
Apr 09

Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition

TIPRANKS
·
Apr 09